Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2
Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
5 April 2022Portfolio NewsNitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research
31 March 2022Portfolio NewsCerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
20 March 2022SV NewsFast-track dementia to curb it like Covid
19 March 2022Portfolio NewsLoQus23: going upstream to slow Huntington’s disease- 18 March 2022Portfolio NewsNitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference
- 2 March 2022Portfolio NewsCaraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD
- 25 January 2022Portfolio NewsLoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director
1 December 2021Portfolio NewsAviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform- 23 November 2021Portfolio NewsLoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
- 2 November 2021Portfolio NewsNitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
- 22 September 2021SV NewsWhy Bill Gates is optimistic about the future of Alzheimer’s research
- 14 September 2021Portfolio NewsQurAlis Announces Development Candidate for ALS Targeting STATHMIN-2
